Why the study?
Ranolazine is an anti-anginal drug with antiarrhythmic properties through late sodium and potassium current inhibition, showing promising results for atrial fibrillation and ventricular arrhythmias.
Does ranolazine improve outcomes in patients with cardiac arrhythmias?
Does ranolazine improve outcomes in patients with cardiac arrhythmias?
Ranolazine, traditionally an anti-anginal medication, shows promise as an antiarrhythmic agent for treating atrial fibrillation and ventricular arrhythmias.
Ranolazine's antiarrhythmic effects remain investigational; leaves open its clinical role pending randomized outcome trials.
Ranolazine is an anti-anginal medication that has demonstrated antiarrhythmic properties by inhibiting both late sodium and potassium currents. Studies have shown promising results for ranolazine in treating both atrial fibrillation and ventricular arrhythmias, particularly when used in combination with other medications. This review explores ranolazine's mechanisms of action and its potential role in cardiac arrhythmias treatment in light of previous clinical studies.
No takes yet. Share an insight, caveat, or question.
Santis et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: